Gase energy, Inc. announced it has signed a second letter of intent (LOI) to acquire Sanatio BioScience Inc. (SBI). Their proprietary patent pending modular system uses biologic components in tandem arrays that target specific cell-types and tissues enhance the natural anti-viral activities within the cells. The company has a near term focus on Covid, but the Sanatio platform can be configured to address new threats as well as strains of existing viruses, including MERS, SARS and influenza, by targeting the appropriate virus specific product in infected cells and tissues.